Pharvaris initiated with a Buy at Guggenheim on HAE potential

As previously reported, Guggenheim initiated coverage of Pharvaris (PHVS) with a Buy rating and $32 price target telling investors that the company is positioned to address both the on-demand and prophylaxis segments of the hereditary angioedema market with once a day, oral medicines. Deucrictibant IR could become a $400M medicine, says the analyst, who sees a “very high chance” of a positive readout in Pharvaris’ RAPIDe-3 Phase 3 trial.